Eli Lilly, the "King of Medicine," hits another record high! JPMorgan raises Eli Lilly's target price! (In-depth)
Eli Lilly (LLY) shares reached a new high on July 8, 2026, with the most direct catalyst beingWall Street investment bank JPMorgan's significant post-market target price raise on July 7.
I. Core Catalyst: JPMorgan Raises Target Price
JPMorgan analyst Chris Schott raised Eli Lilly’s target price from$1,300 to $1,400, maintaining an “Overweight” rating. This target price is significantly higher than Wall Street’s average of $1,243, implying about a17% upside from the July 6 closing price.
The analyst report clearly states the bullish thesis for Eli Lilly is based on:
Sustained volume growth for Mounjaro in international markets
Steady growth in the U.S. obesity market
Estimatedtotal sales this quarter will reach $20.7 billion (about $300 million higher than consensus),EPS of $8.85 (up $0.13)
II. Other Positive Views from Wall Street Banks
Before JPMorgan, other banks had already released positive signals:
| Cantor Fitzgerald | Raised target price from $1,230 to $1,350 , reiterated “Overweight” | July 6 |
| RBC Capital | Reiterated “Outperform” rating, maintained target price at $1,250 | Recently |
| Leerink Partners | Previously raised target price to $1,232 | Previously |
Cantor Fitzgerald specifically noted that large biopharma companies are expected to report overall strong results for Q2 2026 and may drive several companies to raise their full-year revenue guidance.
III. Strong Growth Expectations for the GLP-1 Product Line
Investment bank reports commonly emphasize that Eli Lilly's growth momentum comes from itsGLP-1 weight-loss drug product line:
Zepbound (obesity indication) maintains steady demand in the U.S.
Mounjaro (diabetes indication) continues to expand in international markets
Oral medication orforglipron (Foundayo) andtriple agonist retatrutide and other next-generation assets are still raising market expectations
IV. Recent Additional Positive Factors
Over the past few weeks, Eli Lilly has also accumulated several favorable developments:
U.S. Medicare GLP-1 Bridge Program: Starting July 1, 2026, eligible insured participants are provided access to Zepbound and Foundayo for only $50/month out-of-pocket, which is expected to significantly broaden patient access
Cancer drug Jaypirca receives European support: EMA’s Committee for Medicinal Products for Human Use supports its use in chronic lymphocytic leukemia, paving the way for final EU approval
Sector rotation effect: On July 8, funds rotated from semiconductor stocks to healthcare, with Eli Lilly, as a sector leader, seeing notable benefits
V. Fundamental Data Support
From a fundamental perspective, Eli Lilly’s share price has risen about54%-58% over the past year, with a market capitalization reaching$1.1 trillion. The company’s revenue rose by 47%, its PEG ratio is only 0.33, and its Piotroski score reached a perfect 9, reflecting strong financial health.
Summary: The record high in Eli Lilly’s share price is a direct result ofJPMorgan’s significant target price upgrade, combined withmultiple positive calls from investment banks,strong growth expectations for the GLP-1 product line,several recent positive developments, andsector rotation. The market will closely monitor theQ2 earnings report to be released in August (UTC+8), to verify whether the investment bank forecasts (sales of $20.7 billion, EPS $8.85) materialize.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Wall Street giants collectively raise rate hike forecasts, US Treasury futures continue to fall, gold drops over 1% to break 4000
After the US October CPI exceeded expectations, Goldman Sachs and Nomura added a forecast for an interest rate hike in March next year, while Deutsche Bank included a forecast for a rate hike in January next year. Currently, the market has fully priced in a 25 basis point rate hike in December, with a 13% probability for a 50 basis point hike. On Wednesday, the US Treasury spot market was closed, but Treasury futures continued to fall, with corresponding yields rising by about 2 to 4 basis points, and spot gold came under pressure, dropping by 1.1%.
No Need to Worry About the Cooling Down of AI Data Center Construction? The US Import Boom Is Unlikely to Subside in the Short Term, Real Impact May Come in 2029
It takes an average of 4.8 years from finalizing investment to starting construction of a data center project, and an additional 2.6 years from construction start to becoming operational. Servers usually cannot be installed until after the building structure and racks are completed. For trade partners such as Taiwan (China), South Korea, and Mexico who rely on US data center supply chain demand, the inertia in construction timelines provides at least a one- to two-year buffer for future exports.
Federal Reserve Major Debate: When Should the Tenure of “Number Three” Williams End?
The main point of contention is whether Williams should step down in June 2028, upon completing a full 10-year term, or in June 2027, when he reaches the mandatory retirement age of 65. Analysts point out that the Federal Reserve Board holds ultimate discretion; if he leaves early, Fed Chair Waller would be able to assert greater control over the appointment to this critical position. However, forcing Williams to shorten his term could easily be interpreted as political manipulation. Williams himself is expected to serve until June 2028.
Crypto prices
More
